FDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

Ads

You May Also Like

Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology ...

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, April 24, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced ...

Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

MADISON, Wis., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, ...